Dapagliflozin Significantly Reduced A1C in Children, Adolescents With Type 2 Diabetes

Investigators found that the adjusted mean change in A1C was –0.62% for dapagliflozin compared to 0.41% for a placebo in patients with type 2 diabetes.

Related Keywords

Israel ,Naim Shehadeh ,Maya Kruchancova ,Dapagliflozin Forxiga ,Bio Pharmaceuticals Business Unit At Astrazeneca ,Endocrinology At Rambam Health Care Campus ,Astrazeneca ,Rambam Health Care Campus ,Bio Pharmaceuticals Business Unit ,Annual Meeting ,European Association ,Diabetes Congress ,New England Journal ,